Cocrystal Pharma, Inc. (COCP) shares surged 50.98 percent, up $0.52 to $1.54 on Thursday, after the U.S. Food and Drug Administration granted Fast Track designation to CDI-988, the company's oral antiviral candidate for treatment and prevention of norovirus infection.
The stock is currently trading at $1.54, above its previous close of $1.02, after opening at $1.70 on the Nasdaq. Shares traded in a range of $1.66 to $2.0299 during the session, with volume surging to 74.12 million shares, far above the average daily volume of 0.06 million.
The Fast Track designation allows more frequent communication with the FDA, rolling review of a future New Drug Application, and potential Priority Review. CDI-988 is currently being evaluated in a Phase 1b norovirus challenge study at Emory University School of Medicine as the company aims to develop the first oral antiviral therapy targeting norovirus infections.
Cocrystal Pharma's 52-week range is $0.86 to $2.67.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.